Arbutus Biopharma (ABUS) and Genevant Sciences, a subsidiary of Roivant Sciences (ROIV), on Thursday announced the filing of three international lawsuits over a patent dispute related to Pfizer (PFE) ...

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid ...

The two New Jersey suits assert eight patents against Pfizer and 10 against Moderna, extending existing mRNA litigation ...

Arbutus Biopharma and its licensee Genevant filed three patent infringement lawsuits against Pfizer and BioNTech for its lipid nanoparticle technology. The clinical-stage biopharmaceutical company is ...

As Pfizer and Moderna have tied off certain threads in their separate webs of mRNA patent litigation, Sanofi has opened a new ...

Warminster-based Arbutus Biopharma has cranked up its legal war over COVID‑19 vaccine delivery technology, rolling out a new ...

On July 8, Arbutus received around $178 million from Moderna as part of a patent litigation settlement, the company said.

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine. Siding with Moderna, an American pharmaceutical firm ...

Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their ...